Vaxcyte, Inc.
PCVX
$44.70
-$0.82-1.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -29.46% | -10.12% | -16.67% | -15.33% | -69.49% |
| Total Depreciation and Amortization | 41.67% | 59.53% | 61.43% | 55.79% | 47.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 114.61% | 107.61% | 270.16% | 260.03% | 125.42% |
| Change in Net Operating Assets | 195.96% | 213.92% | -4,376.50% | -167.50% | -135.90% |
| Cash from Operations | -15.34% | 1.57% | -12.63% | -52.51% | -101.56% |
| Capital Expenditure | 46.25% | 9.39% | -80.03% | -75.55% | -1,122.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 88.12% | -186.64% | -84.84% | -167.43% | -68.02% |
| Cash from Investing | 83.93% | -143.37% | -84.38% | -159.36% | -83.87% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.37% | 56.05% | 15.77% | 282.61% | 89.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 18.23% | -141.38% | -152.15% | -268.73% | -281.75% |
| Cash from Financing | -99.82% | 55.45% | 15.15% | 282.69% | 89.09% |
| Foreign Exchange rate Adjustments | 141.98% | -13.90% | -589.95% | 106.37% | -580.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -252.19% | -1,645.20% | -214.33% | 97.86% | 89.26% |